Cannabinoid oral spray - Aphria/Medlab

Drug Profile

Cannabinoid oral spray - Aphria/Medlab

Alternative Names: NanaBidial; NanaBis; Nanocelle™ CBD

Latest Information Update: 25 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aphria; Medlab
  • Developer Medlab
  • Class Analgesics; Antiepileptic drugs; Antipsychotics; Anxiolytics; Cannabinoids; Cyclohexenes; Muscle relaxants; Neuroprotectants; Skin disorder therapies; Small molecules
  • Mechanism of Action Cannabinoid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Pain

Most Recent Events

  • 27 Oct 2017 Medlab plans a pilot pharmacokinetics, safety and tolerability trial of NanaBidial in healthy volunteers in Australia (Buccal) in February 2018 (ACTRN12617001491358)
  • 22 Aug 2016 Early research in Pain in Australia (PO)
  • 22 Aug 2016 Medlab plans a phase I/II study in Pain in Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top